These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 21415462

  • 1. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P.
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [Abstract] [Full Text] [Related]

  • 2. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D, Franz DN.
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [Abstract] [Full Text] [Related]

  • 4. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 5. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.
    Rev Neurol; 2014 Dec 01; 59(11):497-502. PubMed ID: 25418144
    [Abstract] [Full Text] [Related]

  • 6. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.
    N Engl J Med; 2010 Nov 04; 363(19):1801-11. PubMed ID: 21047224
    [Abstract] [Full Text] [Related]

  • 7. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
    Yalon M, Ben-Sira L, Constantini S, Toren A.
    Childs Nerv Syst; 2011 Jan 04; 27(1):179-81. PubMed ID: 20703486
    [Abstract] [Full Text] [Related]

  • 8. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR, Pole JD, Bouffet E, Taylor MD, Bartels U.
    Pediatr Blood Cancer; 2015 Oct 04; 62(10):1754-60. PubMed ID: 25929843
    [Abstract] [Full Text] [Related]

  • 9. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep 04; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 10. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J, Duric V, Ivancevic N, Nikolic B, van den Anker JN, Samardzic J.
    Curr Med Chem; 2016 Sep 04; 23(37):4260-4269. PubMed ID: 27739368
    [Abstract] [Full Text] [Related]

  • 11. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
    Komotar RJ, Starke RM, Connolly ES, Sisti MB.
    Neurosurgery; 2011 Apr 04; 68(4):N24-5. PubMed ID: 21792104
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 16. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex -  pharmacological treatment using mTOR inhibitors].
    Zitterbart K.
    Klin Onkol; 2014 Jan 12; 27(6):401-5. PubMed ID: 25493579
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.
    Wheless JW, Klimo P.
    J Child Neurol; 2014 Nov 12; 29(11):1562-71. PubMed ID: 24105488
    [Abstract] [Full Text] [Related]

  • 20. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.
    J Neuropathol Exp Neurol; 2004 Dec 12; 63(12):1236-42. PubMed ID: 15624760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.